2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

@article{Singh20162015AC,
  title={2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis},
  author={Jasvinder A. Singh and Kenneth G. Saag and S. Louis Bridges and Elie A. Akl and Raveendhara R. Bannuru and Matthew C. Sullivan and Elizaveta E. Vaysbrot and Christine McNaughton and Mikala C. Osani and Robert H. Shmerling and Jeffrey R. Curtis and Daniel E Furst and Deborah Parks and Arthur Kavanaugh and James R. O'dell and Charles King and Amye Leong and Eric L. Matteson and John T Schousboe and Barbara E. Drevlow and Seth Ginsberg and James S. Grober and E. William St.Clair and Elizabeth A. Tindall and Amy S. Miller and Timothy E. McAlindon},
  journal={Arthritis \& Rheumatology},
  year={2016},
  volume={68}
}
To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA). 
Systematic Review of Recommendations on the Use of Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer
TLDR
To evaluate consensus recommendations regarding management of rheumatoid arthritis (RA) in patients with cancer, a meta-analysis of clinical practice and animal studies shows clear trends in prognosis and disease progression. Expand
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
To develop an evidence‐based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and theExpand
Rheumatoid arthritis: Missed opportunities in the 2015 ACR guideline for RA treatment
The new ACR guideline for the treatment of rheumatoid arthritis (RA) is technically solid, but the new recommendations miss some of the most topical issues in RA therapeutics. The fact that evidenceExpand
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
To develop an evidence‐based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and theExpand
Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis
This retrospective analysis examined how sustained remission impacted risk of serious infections in patients with rheumatoid arthritis (RA) enrolled in a clinical registry.
Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature
To review the published studies that dose down and then discontinue biologic therapy in patients with rheumatoid arthritis (RA), particularly concerning the criteria for such dosing and the impact onExpand
Clinical effectiveness of influenza vaccination in patients with rheumatoid arthritis
TLDR
The objective was to determine the clinical effectiveness of influenza vaccination in patients with rheumatoid arthritis (RA) and to establish a protocol for safe and effective vaccination against influenza. Expand
Rheumatoid arthritis: Do TNF inhibitors influence lymphoma development?
TNF inhibition is associated with an increased risk of lymphoma development. But is this association due to the TNF inhibitors themselves or the patient's underlying disease?
Underuse of Methotrexate in the Treatment of Rheumatoid Arthritis: A National Analysis of Prescribing Practices in the US
TLDR
This study examines MTX prescribing practices in the US from 2009 to 2014 to examine the effectiveness, tolerability, and cost of the anchor drug in the treatment of rheumatoid arthritis. Expand
“Official View” on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements
TLDR
The perception of the current role of systemic glucocorticoids in the management of rheumatoid arthritis is described by examining their importance and the current level of evidence in recent guidelines, and open questions are identified. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 154 REFERENCES
Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B
TLDR
This medical record review assessed the safety and efficacy of abatacept in 8 patients with rheumatoid arthritis (RA) and chronic hepatitis B. Expand
The definition and measurement of disease modification in inflammatory rheumatic diseases.
TLDR
These are measures that are used to evaluate disease activity, damage, and function in three major inflammatory musculoskeletal disorders: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expand
Revised criteria for the classification of rheumatoid arthritis.
The Bulletin on the Rheumatic Diseases has published all of the classification criteria for the rheumatic diseases to date. These new revised classification criteria for rheumatoid arthritis are veryExpand
Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register
TLDR
To explore the influence of anti–tumor necrosis factor (anti‐TNF) therapy upon the incidence of cancer in patients with rheumatoid arthritis (RA) and prior malignancy, anti-TNF therapy is introduced into the clinical practice. Expand
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice
TLDR
A Working Group is convened to comprehensively evaluate the validity, feasibility, and acceptability of available RA disease activity measures and derive recommendations for their use in clinical practice. Expand
Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
To compare the effectiveness of rituximab (RTX) or a second anti–tumor necrosis factor (anti‐TNF) therapy in rheumatoid arthritis (RA) patients who had failed their first anti‐TNF and switched toExpand
Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
To compare the efficacy, safety, and tolerability of 4 doses of oral tofacitinib (CP‐690,550) with placebo in Japanese patients with active rheumatoid arthritis (RA) receiving stable backgroundExpand
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the careExpand
Association of Higher Methotrexate Dose With Lymphoproliferative Disease Onset in Rheumatoid Arthritis Patients
TLDR
The clinical characteristics of MTX‐LPD in Japanese RA patients were examined and the risk factors for MTX-associated LPD development were attempted to determine. Expand
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.
TLDR
This work proposes two new definitions of remission that can be uniformly applied and widely used in RA clinical trials, and recommends that one of these be selected as an outcome measure in each trial and that the results on both be reported for each trial. Expand
...
1
2
3
4
5
...